Breaking News

Lilly Opens Diabetes R&D Center in China

Covance to provide services

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eli Lilly and Co. has opened the Lilly China R&D Center (LCRDC), which aims to discover new diabetes medicines with novel mechanisms of action that can be tailored specifically for the Chinese population to delay the progression of the disease. LCRDC will explore the differences in the genetic makeup of Asian patients, which may also play a role in diabetes development and progression.  The LCRDC employs approximately 150 scientists and staff hired primarily from China, and is the latest in ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters